| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Dawn Svoronos is Director at XENE, with reported holdings spanning 2 companies. Dawn Svoronos's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.2M at current prices.
Our model assigns Dawn Svoronos a below-average insider score of 37/100, based on 4 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -7.7%.
Dawn Svoronos's largest disclosed position is in PTCT as Director, worth about $2.0M. Net of sales, the PTCT filings show accumulation of 22,517 shares.
Dawn Svoronos has 26 Form 4 filings on record from June 2016 to September 2026, across 2 companies: Director at Xenon Pharmaceuticals (XENE), 2016–2026; Director at Ptc Therapeutics (PTCT), 2016–2022.
The 34 reported transactions were 20 option or other derivative awards, 6 open-market sales, 3 stock awards and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $478K and 6 sales worth about $1.1M.
The largest open-market purchase was 25,000 shares of PTCT at an average $13.49 on May 23, 2017, about $337K.
The largest open-market sale was 25,000 shares of XENE at an average $38.70 on August 24, 2023, about $968K. Twelve months later XENE was up 6%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2023 | XENE Xenon Pharmaceuticals Inc. | Director | Sell | 25,000 | $38.70 | $967,500.00 | -50.0% | -25.0% | +6.4% | |
| Jun 9, 2022 | PTCT Ptc Therapeutics, Inc. | Director | Sell | 738 | $27.20 | $20,074.34 | -2.5% | +93.1% | +54.4% | |
| Jan 7, 2022 | PTCT Ptc Therapeutics, Inc. | Director | Sell | 510 | $38.53 | $19,647.75 | -1.9% | +12.9% | +3.2% | |
| Jun 9, 2021 | PTCT Ptc Therapeutics, Inc. | Director | Sell | 365 | $41.89 | $15,288.03 | -1.3% | +3.9% | -33.4% | |
| Feb 1, 2021 | PTCT Ptc Therapeutics, Inc. | Director | Sell | 506 | $56.96 | $28,819.74 | -1.8% | - | - | |
| Jun 11, 2020 | PTCT Ptc Therapeutics, Inc. | Director | Sell | 364 | $48.36 | $17,603.04 | -1.4% | - | - | |
| Aug 14, 2017 | XENE Xenon Pharmaceuticals Inc. | Director | Buy | 50,000 | $2.82 | $140,770.00 | New | - | - | |
| May 23, 2017 | PTCT Ptc Therapeutics, Inc. | Director | Buy | 25,000 | $13.49 | $337,230.00 | New | - | - |